Delix Therapeutics

Delix Therapeutics is a biotechnology startup founded in 2019 and headquartered in the United States. The company's slogan, "Repairing the Brain to Heal the Mind," reflects its focus on applying modern pharmaceutical development tools to ancient therapies, specifically psychedelics. Delix has distinguished itself through the identification of a new class of non-hallucinogenic versions of psychedelic compounds with promising safety and therapeutic profiles. The company has garnered attention through its innovative approach and has received a $320.00K grant investment as of 13 December 2023 from the National Institute on Drug Abuse (NIDA). This strategic funding aligns with the company's mission to advance psychoplastogen compounds through preclinical and clinical development, ultimately seeking to address mental suffering with FDA-approved take-home medicines. Delix Therapeutics operates within the biotechnology and health care industries, positioning itself at the forefront of research and development in the emerging field of psychedelic-based treatment. Their pioneering work has the potential to disrupt traditional mental health treatment modalities, marking them as a compelling prospect for venture capital investment.